MMF Immunosuppression

DRUG4 trials

Sponsors

Wondercel Biotech (ShenZhen), University of Patras

Conditions

B Cell LeukemiaB Cell LymphomaB Cell MalignancyHCC - Hepatocellular CarcinomaMultiple MyleomaNSCLC (Advanced Non-small Cell Lung Cancer)Refractory and Relapsed Multiple MyelomaSSc-Systemic Sclerosis

Early Phase 1

Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer

SuspendedNCT06653023

Wondercel Biotech (ShenZhen)HCC - Hepatocellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2024-10-23End: 2027-12-30Target: 60Updated: 2026-05-07

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

SuspendedNCT06662227

Wondercel Biotech (ShenZhen)B Cell Leukemia, B Cell Lymphoma, B Cell Malignancy

Start: 2024-10-24End: 2029-12-30Target: 30Updated: 2026-05-07

Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

SuspendedNCT06663046

Wondercel Biotech (ShenZhen)Multiple Myleoma, Refractory and Relapsed Multiple Myeloma

Start: 2025-07-01End: 2029-12-30Target: 30Updated: 2026-05-07

Unknown Phase

Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD

RecruitingNCT07491523

University of PatrasSSc-Systemic Sclerosis

Start: 2025-06-01End: 2027-03-01Target: 35Updated: 2026-03-24

Related Papers

REVO-U: A next-generation, gene-editing–free universal CAR-T platform to enable ultra–high-yield manufacturing and identification of early clinical activity in relapsed/refractory DLBCL.

Journal of Clinical Oncology2026-05-27